CCM
CORT icon

Coldstream Capital Management’s Corcept Therapeutics CORT Stock Holding History

Coldstream Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,910
Closed -$242K – 1177
2025
Q3 		$242K Buy
+2,910
New +$211K ﹤0.01% 1042
2025
Q2 		– Sell
-2,350
Closed -$268K – 1599
2025
Q1 		$268K Buy
+2,350
New +$143K 0.01% 864

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coldstream Capital Management's CORT Position: Q4 2025 in Review

Coldstream Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 2,910 shares — an estimated $242K sold.

Coldstream Capital Management first reported a position in CORT in Q1 2025 and held it in 2 quarters. The position peaked at $268K in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Coldstream Capital Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 2,910 Corcept Therapeutics shares in Q4 2025, an estimated $242K.
  • Coldstream Capital Management first reported a position in Corcept Therapeutics in Q1 2025 and held it in 2 quarters.
  • Coldstream Capital Management's Corcept Therapeutics position peaked at $268K in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Coldstream Capital Management's 13F filing for Q4 2025, filed 9 Feb 2026.